TMS Co., Ltd. (JP:4891) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TMS Co., Ltd. has announced the publication of Phase 2a clinical trial results for JX10 (TMS-007), a potential treatment for acute ischemic stroke, in a leading medical journal. The study demonstrated significant efficacy and safety, highlighting JX10’s potential as a novel therapeutic option with an extended treatment window. This development marks a promising step forward in addressing the needs of a largely underserved patient population.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.